Previous close | 5.39 |
Open | 5.49 |
Bid | 5.28 x 1400 |
Ask | 5.57 x 800 |
Day's range | 5.20 - 5.56 |
52-week range | 4.86 - 22.49 |
Volume | |
Avg. volume | 462,154 |
Market cap | 58.965M |
Beta (5Y monthly) | 1.59 |
PE ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | N/A |
Apellis (APLS) reports first-quarter 2024 results, wherein earnings match the Zacks Consensus Estimate and revenues beat the same, driven by strong sales of Syfovre.
Blueprint (BPMC) gains from better-than-expected first-quarter 2024 results, driven by robust Ayvakit sales growth. The company raises its revenue guidance for 2024.
Zoetis (ZTS) reports better-than-expected first-quarter results, wherein both earnings and revenues beat estimates. Shares rise.